https://www.globenewswire.com/news-release/2021/11/10/2331897/0/en/Yamo-Pharmaceuticals-Receives-Investment-from-Autism-Impact-Fund-to-Support-Phase-2-Study-of-L1-79-in-Autism-Spectrum-Disorder.html